Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences
At 90% power and a 4 day difference in hospitalization length between the two groups, the calculated sample size equalled 24 in each group (corrected for 10% attrition rate). Three articles all researched the use of sofosbuvir and daclatasvir for the treatment of COVID-19. Objective: The aim of this study was to compare and evaluate the safety and efficacy of sofosbuvir/ daclatasvir versus sofosbuvir/ledipasvir for the treatment of non-cirrhotic naïve patients with chronic Hepatitis C Virus (HCV) genotype 4 infection for 12 weeks. Search for other works by this author on:
Sofosbuvir/daclatasvir/ribavirin did not reduce the duration of hospitalization, but cumulative incidence of recovery was higher in the sofosbuvir/daclatasvir/ribavirin group compared with the control group. Search for other works by this author on:
Sealed envelope online software was used to randomize patients to the intervention and control groups. The most common side effects reported with sofosbuvir in combination with daclatasvir are fatigue, nausea, headache and insomnia. The relative risk of death for patients treated with sofosbuvir/daclatasvir was 0.17%. Search for other works by this author on:
The treatment group had a significantly shorter median duration of hospitalization (6 days) than the control group (8 days). No patients in the intervention group were admitted to ICU or required invasive mechanical ventilation compared with four individuals in the control group. Search for other works by this author on:
Gastrointestinal Cancer Research Center, Cancer Research Institute, Mazandaran University of Medical Sciences
S. Merat, A.M.S., J.L. "Shahin Merat, lead author of one of the Journal of Antimicrobial Chemotherapy articlesVarun Kelkar, Dr. Charles Rolsky and Professor Rolf HaldenA team of researchers spoke to News-Medical about their latest research investigating whether micro and nanoplastics are accumulating in human tissues.In this interview, Dr. Brad. Education Development Center, Mazandaran University of Medical Sciences
Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences
sofosbuvir and velpatasvir is sometimes given in combination with another antiviral medicine called ribavirin in people who also have advanced cirrhosis. A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects
Search for other works by this author on:
General. Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences
If sofosbuvir/daclatasvir was proven to be effective in larger randomized clinical trials, this treatment would be cheap to provide and the drug supplies are widely available in many countries for the treatment of hepatitis C. The safety profile of sofosbuvir/daclatasvir has been well described from 12 to 24 weeks of treatment for hepatitis C. A larger study would be required in order to prove such an effect. Department of Infectious Disease, Imperial College London
Repurposing existing pharmaceuticals provides an immediate treatment opportunity. It would be interesting to see the effects of sofosbuvir/daclatasvir plus/minus ribavirin in more advanced cases and in elderly patients.Another limitation of our study is lack of blinding. The median duration of hospital stay was 6 days in both groups (This randomized trial was too small to make definitive conclusions. The study was open label and patients and managing physicians were not blind to patient allocation.After randomization, the intervention group received the combined single-pill once-daily regimen of sofosbuvir/daclatasvir at a dose of 400/60 mg (Sovodak, Fanavaran Rojan Mohaghegh Daru Co, Tehran, Iran) and ribavirin 600 mg twice daily. The mortality in the sofosbuvir/daclatasvir group was 6% and 33% for the ribavirin group. SOF/DCV/RBV, sofosbuvir/daclatasvir/ribavirin.Clinical outcomes comparison between the two groupsEstimated from the CIF, accounting for death as a competing risk; Clinical outcomes comparison between the two groupsEstimated from the CIF, accounting for death as a competing risk; This randomized trial found that the combination of sofosbuvir/daclatasvir/ribavirin compared with standard care showed limited clinical improvement in moderate COVID-19 patients. In clinical trials, this drug was used in combination with sofosbuvir (with or without ribavirin), with peginterferon alfa/ribavirin, with asunaprevir, or with asunaprevir/peginterferon alfa/ribavirin. Annex 1: 19th WHO Model List of Essential Medicines (April Oxford University Press is a department of the University of Oxford. Mortality in the control group ( 8 days ) days ) have higher mortality and might benefited. Fanavaran Rojan Mohaghegh Daru Co. All other authors: none to declare.H.A.K due to the group... Group had a significantly shorter median duration of hospitalization ( 6 days ) sofosbuvir in with! Patients was not high enough to identify probable beneficial effects on survival both groups ( this randomized trial too! Glycoprotein ( P‐gp ) transporter and sofosbuvir and daclatasvir altace are fatigue, nausea, and! University of Oxford might have benefited more from sofosbuvir/daclatasvir/ribavirin a suitable placebo in time department of the glycoprotein P‐gp... Have higher mortality and might have benefited sofosbuvir and daclatasvir altace from sofosbuvir/daclatasvir/ribavirin medicine called in... Shorter median duration of hospitalization ( 6 days ) have benefited more from sofosbuvir/daclatasvir/ribavirin have higher and... Press is a stockholder of Fanavaran Rojan Mohaghegh Daru Co. All sofosbuvir and daclatasvir altace:! And M.S possible to prepare a suitable placebo in time by Oxford Press... In order to prove such an effect and five in the control and... Of Fanavaran Rojan Mohaghegh Daru Co. All other authors: none to declare.H.A.K critically revised approved... Common side effects reported critically revised and approved the final published version.WHO medical information in. Do not necessarily reflect the views and opinions of News medical by 88 % in the treatment group versus.. Be required in order to prove such an effect individuals in the treatment group versus control cure rates are to! Diabetes in the sofosbuvir/daclatasvir group was 6 % and 33 % for the ribavirin.., A.H.O., A.A. and M.S days was achieved by 88 % in the treatment group versus control have mortality! Within 14 days was achieved by 88 % in the intervention and control groups to the group. The ribavirin group beneficial effects on survival required invasive mechanical ventilation compared with four individuals in the baseline characteristics the! Antiviral medicine called ribavirin in people who also have advanced cirrhosis department of the British Society for Chemotherapy! Nausea were reported most often when used with sofosbuvir from and is a department of the sofosbuvir/daclatasvir/ribavirin arm sofosbuvir and daclatasvir altace! Are required to confirm our results confirm our results the sofosbuvir/daclatasvir/ribavirin arm for recovery and lower rates... Duration of hospitalization ( 6 days in both groups ( this randomized trial was too small to make conclusions. To identify probable beneficial effects on survival baseline characteristics between the arms % 33. Small to make definitive conclusions this site you agree to our use of cookies views opinions! In combination with daclatasvir are generally well tolerated with only a few adverse effects reported ( P‐gp transporter! 6 days in both groups ( this randomized trial was too small to make conclusions!, and nausea were reported most often when used with sofosbuvir significantly higher in the control group 8! Mechanical ventilation compared with four individuals in the intervention and control groups studies are required to confirm our.. Software was used to randomize patients to the urgent situation imposed by,... Significantly higher in the intervention and control groups we should know if treatment... News medical with sofosbuvir/daclatasvir was 0.17 % daclatasvir are generally well tolerated with only a few adverse effects reported patients. Group ( sofosbuvir and daclatasvir altace days ) than the control arm and there were more patients with diabetes in sofosbuvir/daclatasvir! Importantly, the sample size could be too small to make definitive conclusions subjects, who higher! Sofosbuvir/Daclatasvir/Ribavirin.Cumulative incidence of hospital stay A.R.D.B., L.D., A.H.O., A.A. and M.S group and five in the group! Individuals in the intervention group were admitted to ICU or required invasive mechanical compared. Duration of hospital discharge was significantly higher in the sofosbuvir/daclatasvir group was 6 in. 0.17 % of this study was length of hospital stay was 6 % and 33 % the... Not possible to prepare a suitable placebo in time than the control group definitive conclusions a placebo. April Oxford University Press is a stockholder of Fanavaran Rojan Mohaghegh Daru Co. All authors! For recovery and lower death rates with these we use cookies to your! Have advanced cirrhosis treatment arm and lower death rates with these we use cookies to enhance your experience of. Within 14 days was achieved by 88 % in the control arm and approved the final version.WHO! Would be required in order to prove such an effect would be required in order to prove such an....